This is a renewal application for continuing research in clinical cancer as a member of CALGB. The New York Hospital - Cornell Medical Center together with North Shore University Hospital and affiliated institutions remain a major contributor to the scientific, clinical and administrative activities of CALGB. Our multidisciplinary growth is reflected in our clinical activities (our group is now the leading contributor to CALGB studies) and our participation in CALGB affairs. Leadership activities are reflected in our administrative and scientific contributions to CALGB, our multidisciplinary growth, and in our pilot and phase II programs.
Our aims are to participate in a cooperative approach in the design and conduct of therapeutic trials in cancer. In this context we will (1) determine the effect, extent and duration of remission and other responses to treatment of the diseases of concern to CALGB, (2) study the natural history, immunologic aspects, cytogenetics, and molecular biology of the diseases investigated by CALGB, (3) participate in pilot, phase II and multidisciplinary trials of CALGB, (4) continue the high level of patient accrual and data collection of the recent grant years, (5) continue our vigorous participation in Group activities as it pertains to Group science and Group administration.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA007968-28
Application #
3555906
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-04-01
Project End
1993-03-31
Budget Start
1992-04-15
Budget End
1993-03-31
Support Year
28
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
Schools of Medicine
DUNS #
201373169
City
New York
State
NY
Country
United States
Zip Code
10065
Gajra, Ajeet; McCall, Linda; Muss, Hyman B et al. (2018) The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). J Geriatr Oncol 9:221-227
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Brown, Paul D; Ballman, Karla V; Cerhan, Jane H et al. (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CECĀ·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049-1060
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Kohman, Leslie J; Gu, Lin; Altorki, Nasser et al. (2017) Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503. J Thorac Cardiovasc Surg 153:1592-1597
Martin, P; Jung, S-H; Pitcher, B et al. (2017) A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol 28:2806-2812
Smith, Sonali M; Pitcher, Brandelyn N; Jung, Sin-Ho et al. (2017) Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol 4:e176-e182

Showing the most recent 10 out of 112 publications